NIT
DNLI icon

NumerixS Investment Technologies’s Denali Therapeutics DNLI Stock Holding History

NumerixS Investment Technologies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,304
Closed -$80K – 233
2020
Q2 		$80K Buy
+3,304
New +$77.7K 0.02% 656
2020
Q1 		– Sell
-3,606
Closed -$63K – 1062
2019
Q4 		$63K Buy
3,606
+2,606
+261% +$43.4K 0.01% 767
2019
Q3 		$15K Sell
1,000
-800
-44% -$15.3K ﹤0.01% 906
2019
Q2 		$37K Sell
1,800
-850
-32% -$19K 0.01% 830
2019
Q1 		$60K Buy
+2,650
New +$55.4K 0.01% 962

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NumerixS Investment Technologies's DNLI Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 3,304 shares — an estimated $80K sold.

NumerixS Investment Technologies first reported a position in DNLI in Q1 2019 and held it in 5 quarters. The position peaked at $80K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • NumerixS Investment Technologies reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 3,304 Denali Therapeutics shares in Q3 2020, an estimated $80K.
  • NumerixS Investment Technologies first reported a position in Denali Therapeutics in Q1 2019 and held it in 5 quarters.
  • NumerixS Investment Technologies's Denali Therapeutics position peaked at $80K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.